---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-041571"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:15:32.396041+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enanta reports Q3 fiscal 2021 net loss of $24.0M; nominates COVID-19 protease inhibitor EDP-235

## Summary
- Royalty revenue $21.6M from AbbVie's HCV regimen; net loss $24.0M ($1.19/sh) vs loss $14.3M ($0.71/sh) year ago.
- Cash and securities $372.5M; R&D expenses increased to $47.0M from $34.7M.
- Nominated EDP-235 oral protease inhibitor for SARS-CoV-2; Phase 1 study planned for early 2022.
- Positive Phase 1b data for EDP-514 in viremic HBV patients: mean HBV DNA reduction 3.3 logs.
- Planned retirement of CMO Nathalie Adda, M.D. in February 2022.

## SEC filing metadata
- accession: 0001564590-21-041571
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000156459021041571/0001564590-21-041571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000156459021041571/enta-8k_20210805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-041571
- JSON: https://secwatch.observer/filing/0001564590-21-041571.json
- Plain text: https://secwatch.observer/filing/0001564590-21-041571.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.